Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Leap Therapeutics Inc LPTX

Healthcare Biotechnology
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic... see more

Recent & Breaking News (NDAQ:LPTX)

Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting

GlobeNewswire March 14, 2018

Leap Therapeutics to Present at 2018 Barclays Global Healthcare Conference

GlobeNewswire March 7, 2018

Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Announces Date of its Annual Meeting of Stockholders

GlobeNewswire February 23, 2018

Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference

GlobeNewswire February 6, 2018

Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial

GlobeNewswire January 16, 2018

Leap Therapeutics Announces $18 Million Private Placement Offering

GlobeNewswire November 15, 2017

Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial

GlobeNewswire November 13, 2017

Leap Therapeutics to Present at the 2017 Ladenburg Thalmann Healthcare Conference

GlobeNewswire September 19, 2017

Leap Therapeutics Announces Collaboration With EORTC to Evaluate DKN-01 in Combination with PD-L1 Cancer Immunotherapy and Chemotherapy In Esophagogastric and Biliary Tract Cancers

GlobeNewswire September 8, 2017

Leap Therapeutics Reports Second Quarter 2017 Financial Results

GlobeNewswire August 11, 2017

Leap Therapeutics Added to Russell Microcap® Index

GlobeNewswire June 26, 2017

Leap Therapeutics Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with DKN-01 in Esophagogastric Cancer

GlobeNewswire June 21, 2017

Leap Therapeutics to Present at Two Investor Conferences in June

GlobeNewswire June 1, 2017

The Most Notable Abstracts Released Ahead Of ASCO 2017

Benzinga.com  May 19, 2017

Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

GlobeNewswire May 17, 2017

Leap Therapeutics Reports First Quarter 2017 Financial Results

GlobeNewswire May 12, 2017

Leap Therapeutics to Present DKN-01 Clinical Data at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

GlobeNewswire April 20, 2017

Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 and DKN-01 at the 2017 AACR Annual Meeting

GlobeNewswire April 3, 2017

Leap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers

GlobeNewswire March 31, 2017

Leap Therapeutics to Present at Two Investor Conferences in April

GlobeNewswire March 29, 2017